Citigroup Cuts IQVIA (NYSE:IQV) Price Target to $200.00

IQVIA (NYSE:IQV) had its target price cut by Citigroup from $230.00 to $200.00 in a report released on Friday morning,Benzinga reports. They currently have a neutral rating on the medical research company’s stock.

Several other equities analysts have also issued reports on IQV. Evercore reiterated an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research report on Thursday. UBS Group reduced their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Morgan Stanley upped their target price on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, TD Cowen lifted their price target on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.75.

IQVIA Trading Up 3.6%

IQV opened at $187.50 on Friday. The firm’s fifty day moving average is $228.03 and its two-hundred day moving average is $209.87. The firm has a market cap of $31.93 billion, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.90 and a beta of 1.37. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA during the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. increased its position in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new stake in IQVIA in the fourth quarter valued at approximately $27,000. Westside Investment Management Inc. lifted its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA during the 3rd quarter worth approximately $30,000. 89.62% of the stock is owned by institutional investors.

IQVIA News Roundup

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.